In recognition of the pleiotropic actions of gastrointestinal hormones in the regulation of metabolic homeostasis, exogenous peptides or mimetics (e.g., GLP-1 receptor agonists and GLP-1/GIP dual receptor agonists) are under rapid development within the pharmaceutical industry to better manage both type 2 diabetes and obesity. This evidence concerns the gene GLP1R and obesity disorder.